{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:39:13Z","timestamp":1768714753083,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"S57","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4710,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1996,6]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Abelcet\u00ae, or Amphotericin B Lipid Complex, is a unique formulation, comprising an equimolar mixture of amphotericin B complexed with two lipids. In preclinical studies, Abelcet\u00ae was clearly demonstrated to be less toxic than amphotericin B desoxycholate and to be effective in models where amphotericin B was ineffective at its maximum tolerated dose. Pharmacokinetic studies in animals also showed that the concentration of Abelcet\u00ae in blood is similar or reduced compared to levels seen with conventional amphotericin B, with accumulation in the liver, lungs and spleen. Phase I clinical trials determined the optimum tolerated dose of Abelcet\u00ae to be 5 mg\/kg d<jats:sup>\u20101<\/jats:sup>. Data are now available for 228 cases (including 51 paediatric cases) of invasive fungal infection treated with Abelcet\u00ae in an open\u2010label emergency\u2010release protocol. All patients had to have failed on previous amphotericin B or other conventional antifungals, or to have unacceptable toxicity on amphotericin B, or underlying renal disease, or nephrotoxicity due to other drugs. Abelcet\u00ae was administered at a dose of 5 mg\/kg d<jats:sup>\u20101<\/jats:sup> for 4 wk. Approximately one\u2010third of patients had candidiasis, one\u2010third aspergillosis and one\u2010third other infections, including fusariosis. Of 183 cases evaluable for response, 126 (69%) had a clinical response (cure or improvement) which was mycologically confirmed in 55% (61\/110 tested). Results in paediatric cases were similar to or better than those seen in the group as a whole. When comparisons were made between cases with different types of infection, underlying disease\/immunosuppressive disorder, and degree of neutropenia, the response rates were very consistent from group to group. Treatment with Abelcet\u00ae was well tolerated and mean serum creatinine levels actually declined during therapy, particularly in patients with pre\u2010existing renal dysfunction.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1996.tb01348.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T17:24:35Z","timestamp":1279473875000},"page":"18-23","source":"Crossref","is-referenced-by-count":67,"title":["Amphotericin B Lipid Complex (Abelcet\u00ae) in the treatment of invasive mycoses: the North American experience"],"prefix":"10.1111","volume":"56","author":[{"given":"J.","family":"Lister","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/13.3.496"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005020-00003"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(94)95986-2"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.16.6122"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-3084(90)90114-7"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0300-9084(89)90130-2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1991.tb03189.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150730"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1993.tb00605.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(89)90336-2"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681219280000491"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.615"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.10.2144"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.3.353"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01104273"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.1.73"},{"key":"e_1_2_1_18_2","unstructured":"The Liposome Company. Data on file 1993."},{"key":"e_1_2_1_19_2","first-page":"306a","article-title":"Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy","volume":"84","author":"Lister J.","year":"1994","journal-title":"Blood"},{"issue":"8","key":"e_1_2_1_20_2","first-page":"202","article-title":"Safety and efficacy of amphotericin B lipid complex (ABLC) in neutropenic patients with life\u2010threatening mycoses","volume":"5","author":"Hiemenz JW","year":"1994","journal-title":"Ann Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1996.tb01348.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1996.tb01348.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:06:04Z","timestamp":1698332764000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1996.tb01348.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,6]]},"references-count":19,"journal-issue":{"issue":"S57","published-print":{"date-parts":[[1996,6]]}},"alternative-id":["10.1111\/j.1600-0609.1996.tb01348.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1996.tb01348.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,6]]}}}